BRCA1 and breast cancer: Furthermore, in the latest large multiple center study (23), 1,583 patients with BRCA1 mutations and 881 with BRCA2 mutations, 383 (24%) and 454 (52%) of patients were administered tamoxifen, respectively, following the initial breast cancer diagnosis.